{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_16", "document_index": 84, "latency_s": 0.7780542999971658, "prompt_toks": 6422, "completion_toks": 80, "relevance_score": 6.6295206e-07}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    United States: Cannabidiol is legal under the 2018 Farm Bill[37]. The rest of the cannabis plant (anything with more than 0.3% Delta-9-THC) is still under Schedule I of the Controlled Substances Act.[citation needed]\n\nExternal links\n\nCannabidiol (Wikipedia)\n\nCannabidiol (Isomer Design)\n\nCannabidiol (Drugs-Forum)\n\nProject CBD\n\nLiterature\n\nMechoulam, R., Peters, M., Murillo-Rodríguez, E., & Hanuš, L.O. (2007). Cannabidiol--recent advances. Chemistry & Biodiversity, 4 8, 1678-92.\n\nMechoulam, R., Parker, L. A., & Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. The Journal of Clinical Pharmacology, 42(S1).\n\nDevinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., ... & Martinez‐Orgado, J. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802. https://doi.org/0.1111/epi.12631\n\nReferences\n\n\n                    Context: \n                    This chunk provides information on the legal status of cannabidiol in the United States, highlighting its legality under the 2018 Farm Bill and its classification under Schedule I of the Controlled Substances Act. It also includes external links and key literature references relevant to cannabidiol research and regulation, complementing the overall focus on CBD's effects, safety, and legal considerations within the full document.\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_8", "document_index": 84, "latency_s": 0.6196342000039294, "prompt_toks": 6323, "completion_toks": 62, "relevance_score": 5.203571e-07}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    Cannabidiol is metabolized in the liver and intestines by enzymes CYP2C19 and CYP3A4, and UGT1A7, UGT1A9, and UGT2B7 isoforms.[19]\n\nSubjective effects\n\nThis subjective effects section is a stub . As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.\n\nDisclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.\n\nIt is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.\n\nPhysical effects\n\n\n                    Context: \n                    This excerpt covers the metabolic pathways of cannabidiol in the human body and provides an introduction to its subjective effects, noting the current lack of comprehensive data. This section is relevant for understanding CBD's pharmacokinetics and potential user experience, contributing to the overall safety and effects profile outlined in the full document.\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_15", "document_index": 84, "latency_s": 0.8761873999901582, "prompt_toks": 6320, "completion_toks": 72, "relevance_score": 5.043474e-07}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    Hong Kong: Illegal in Hong Kong since 1st February 2023, punishable by 7 years imprisonment.[33]\n\nNew Zealand: Cannabidiol is a controlled substance in New Zealand. However, by passing the Misuse of Drugs Amendment Regulations 2017 in September 2017, many of the restrictions currently imposed by the regulations are removed since then. The changes will mean that CBD products, where the level of other naturally occurring cannabinoids is less than 2% of the cannabinoid content, will be easier to access for medical use.[34]\n\nSwitzerland: Cannabidiol is not subject to the Narcotics Act in Switzerland because it does not produce a psychoactive effect. It is still subject to standard Swiss legislation.[35]\n\nUnited Kingdom: In 2016, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a statement that products containing CBD used for medical purposes are considered as a medicine subject to standard licensing requirements.[36]\n\n\n                    Context: \n                    This excerpt summarizes the legal status of cannabidiol (CBD) in various countries, highlighting recent regulations and enforcement. It details restrictions and allowances in Hong Kong, New Zealand, Switzerland, and the United Kingdom, providing key regulatory updates relevant to understanding CBD's legal landscape globally. This information is essential for users seeking legal guidance on CBD use across different jurisdictions.\n                "}
